Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (FRA:GU5)
Germany flag Germany · Delayed Price · Currency is EUR
1.990
-0.030 (-1.49%)
At close: Jan 23, 2026

FRA:GU5 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
77,32574,77975,27570,55068,75861,450
Other Revenue
214.3214.3240.53237.96256.1223.35
77,53974,99375,51570,78869,01461,674
Revenue Growth (YoY)
1.50%-0.69%6.68%2.57%11.90%-5.05%
Cost of Revenue
64,67562,51861,37357,54855,82551,282
Gross Profit
12,86412,47514,14313,24013,18910,392
Selling, General & Admin
8,1218,0038,4848,0627,9556,396
Research & Development
628.98763.77782.14819.45874.72611.93
Other Operating Expenses
239.54175.296.38-182.76294.43257.59
Operating Expenses
9,1559,0019,3468,7539,2197,365
Operating Income
3,7093,4744,7964,4873,9703,026
Interest Expense
-406.58-418.15-446.19-434.41-417.83-363.34
Interest & Investment Income
606.61698.33751.181,048757.45718.04
Currency Exchange Gain (Loss)
-3.15-3.153.32-11.128.672.1
Other Non Operating Income (Expenses)
36.34-25.74-45.01-41.12-94.44-66.85
EBT Excluding Unusual Items
3,9423,7255,0605,0484,2243,316
Gain (Loss) on Sale of Investments
-399.02-361.0138.64-3.59196.88-16.14
Gain (Loss) on Sale of Assets
14.6411.1212.030.690.692.95
Asset Writedown
-7.3-2.930.42-7.06-3.08-2.89
Legal Settlements
-----24.82-12.02
Other Unusual Items
235.17235.17-0.364.76329.44450.86
Pretax Income
3,7863,6085,1105,0434,7233,739
Income Tax Expense
676.23606.85851.17789.87754.09647.45
Earnings From Continuing Operations
3,1093,0014,2594,2533,9693,092
Minority Interest in Earnings
-122.84-165.24-203.65-286.85-249.11-176.38
Net Income
2,9872,8354,0563,9673,7202,915
Net Income to Common
2,9872,8354,0563,9673,7202,915
Net Income Growth
-12.76%-30.09%2.25%6.63%27.60%-8.58%
Shares Outstanding (Basic)
1,6261,6261,6261,6261,6261,626
Shares Outstanding (Diluted)
1,6261,6261,6261,6261,6261,626
Shares Change (YoY)
0.01%0.02%-0.02%---
EPS (Basic)
1.841.742.502.442.291.79
EPS (Diluted)
1.841.742.502.442.291.79
EPS Growth
-12.77%-30.10%2.27%6.63%27.61%-8.57%
Free Cash Flow
996.372,3142,4755,6154,419-291.32
Free Cash Flow Per Share
0.611.421.523.452.72-0.18
Dividend Per Share
0.8000.8000.7490.7320.6870.538
Dividend Growth
-30.37%6.81%2.32%6.55%27.69%-8.66%
Gross Margin
16.59%16.63%18.73%18.70%19.11%16.85%
Operating Margin
4.78%4.63%6.35%6.34%5.75%4.91%
Profit Margin
3.85%3.78%5.37%5.60%5.39%4.73%
Free Cash Flow Margin
1.29%3.09%3.28%7.93%6.40%-0.47%
EBITDA
4,2504,0685,4625,0024,3903,415
EBITDA Margin
5.48%5.42%7.23%7.07%6.36%5.54%
D&A For EBITDA
541.12594.35665.32514.44419.91388.93
EBIT
3,7093,4744,7964,4873,9703,026
EBIT Margin
4.78%4.63%6.35%6.34%5.75%4.91%
Effective Tax Rate
17.86%16.82%16.66%15.66%15.97%17.32%
Revenue as Reported
2,546----61,674
Advertising Expenses
-930.481,082960.691,054690.74
Source: S&P Global Market Intelligence. Standard template. Financial Sources.